Analysis Version
v1
History
Back to Study: Restoring mortality data in the FOURIER cardiovasc...
quantitative
Analysis v1
Strong Support

A second look at heart death data from a major drug trial found more heart-related deaths in the treatment group than were first reported, while the placebo group had fewer — suggesting the original study may have missed some key facts.

80
Pro
0
Against

Evidence from Studies

Supporting (1)

80

Community contributions welcome

80

Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data

Cross-Sectional Study
Human
2022 Dec 30

The study found that more heart attack deaths were missed in the evolocumab group than originally reported, and fewer in the placebo group, which is exactly what the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data

Score: 80
DOI: 10.1136/bmjopen-2021-060172

Similar Assertions

People with heart disease who took a drug called evolocumab had more heart-related deaths than those who took a dummy pill, according to a reanalysis of a major study — but the difference wasn’t quite strong enough to rule out chance.

80
0
77%

People taking a cholesterol drug called evolocumab had almost twice as many heart failure deaths as those on a dummy pill in one big study, but this wasn’t mentioned in the main report—so scientists are wondering if the drug might actually harm the heart in some ways.

80
0
75%

For people at high risk for heart problems because of diabetes or clogged arteries, taking a drug called evolocumab every two weeks can lower their chances of having a heart attack, stroke, or needing heart surgery by about 1 in 5 over nearly 5 years, compared to those who don’t take it.

95
0
70%